(0.14%) 5 529.50 points
(0.17%) 39 538 points
(0.09%) 19 945 points
(0.23%) $81.73
(-1.35%) $2.57
(-0.06%) $2 338.20
(-0.22%) $29.50
(-0.56%) $996.30
(-0.31%) $0.930
(-0.34%) $10.64
(-0.14%) $0.790
(1.81%) $87.27
-2.33% HKD 10.08
Live Chart Being Loaded With Signals
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China...
Stats | |
---|---|
Tagesvolumen | 347 400 |
Durchschnittsvolumen | 175 455 |
Marktkapitalisierung | 3.32B |
EPS | HKD0.760 ( Q4 | 2023-12-31 ) |
Last Dividend | HKD0.479 ( 2023-07-04 ) |
Next Dividend | HKD0 ( N/A ) |
P/E |
8.06 (Sector) 14.27 (Industry) 0 |
ATR14 | HKD0.0420 (0.42%) |
China Isotope & Radiation Korrelation
10 Am meisten positiv korreliert |
---|
10 Am meisten negativ korreliert |
---|
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
China Isotope & Radiation Korrelation - Währung/Rohstoff
China Isotope & Radiation Finanzdaten
Annual | 2023 |
Umsatz: | HKD6.63B |
Bruttogewinn: | HKD3.48B (52.48 %) |
EPS: | HKD1.160 |
FY | 2023 |
Umsatz: | HKD6.63B |
Bruttogewinn: | HKD3.48B (52.48 %) |
EPS: | HKD1.160 |
FY | 2022 |
Umsatz: | HKD6.15B |
Bruttogewinn: | HKD3.51B (57.18 %) |
EPS: | HKD1.220 |
FY | 2021 |
Umsatz: | HKD5.14B |
Bruttogewinn: | HKD3.24B (63.03 %) |
EPS: | HKD1.050 |
Financial Reports:
No articles found.
China Isotope & Radiation Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.479 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.169 | 2018-11-28 |
Last Dividend | HKD0.479 | 2023-07-04 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 6 | -- |
Total Paid Out | HKD1.597 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 2.59 | -- |
Div. Sustainability Score | 9.12 | |
Div.Growth Potential Score | 4.44 | |
Div. Directional Score | 6.78 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.
Ex Date | Amount | Declaration Date | Record Date | Payment Date |
---|---|---|---|---|
04 Jul 2023 | HKD0.479 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
25 May 2022 | HKD0.440 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
17 May 2021 | HKD0.217 | 30 Nov -0001 | 30 Nov -0001 | 30 Nov -0001 |
06 Jul 2020 | HKD0.152 | 31 Mar 2020 | 07 Jul 2020 | 28 Aug 2020 |
03 Jul 2019 | HKD0.139 | 29 Mar 2019 | 04 Jul 2019 | 28 Aug 2019 |
28 Nov 2018 | HKD0.169 | 29 Aug 2018 | 29 Nov 2018 | 31 Jan 2019 |
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
1283.HK | Ex Dividend Junior | 2023-09-22 | Semi-Annually | 0 | 0.00% | |
3692.HK | Ex Dividend Knight | 2023-09-15 | Semi-Annually | 0 | 0.00% | |
0842.HK | Ex Dividend Junior | 2023-09-04 | Sporadic | 0 | 0.00% | |
2039.HK | Ex Dividend Junior | 2023-07-25 | Annually | 0 | 0.00% | |
0390.HK | Ex Dividend Junior | 2023-07-19 | Annually | 0 | 0.00% | |
1571.HK | Ex Dividend Knight | 2023-09-28 | Semi-Annually | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% | |
6812.HK | Ex Dividend Junior | 2023-08-04 | Sporadic | 0 | 0.00% | |
1052.HK | Ex Dividend Junior | 2023-11-03 | Annually | 0 | 0.00% | |
2348.HK | Ex Dividend Knight | 2023-09-19 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0559 | 1.500 | 8.88 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0281 | 1.200 | 9.06 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0811 | 1.500 | -0.210 | -0.315 | [0.1 - 1] |
payoutRatioTTM | 0.380 | -1.000 | 6.20 | -6.20 | [0 - 1] |
currentRatioTTM | 1.926 | 0.800 | 5.37 | 4.29 | [1 - 3] |
quickRatioTTM | 1.603 | 0.800 | 5.28 | 4.22 | [0.8 - 2.5] |
cashRatioTTM | 0.675 | 1.500 | 7.36 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.129 | -1.500 | 7.86 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.266 | 2.00 | 9.91 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | -2.54 | 2.00 | -1.270 | -2.54 | [0 - 20] |
debtEquityRatioTTM | 0.361 | -1.500 | 8.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.525 | 1.000 | 4.59 | 4.59 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.113 | 1.000 | 9.74 | 9.74 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.0501 | 1.000 | -0.833 | -0.833 | [0.2 - 2] |
assetTurnoverTTM | 0.503 | 0.800 | 9.98 | 7.98 | [0.5 - 2] |
Total Score | 9.12 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 8.09 | 1.000 | 9.28 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0811 | 2.50 | -0.135 | -0.315 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -2.54 | 2.00 | -0.847 | -2.54 | [0 - 30] |
dividendYielPercentageTTM | 12.10 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.266 | 2.00 | 9.91 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.380 | 1.500 | 6.20 | -6.20 | [0 - 1] |
pegRatioTTM | 0.633 | 1.500 | 9.11 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.0128 | 1.000 | -2.18 | 0 | [0.1 - 0.5] |
Total Score | 4.44 |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
China Isotope & Radiation
China Isotope & Radiation Corporation engages in the research and development, manufacture, and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications in China. It operates through five segments: Pharmaceuticals; Radioactive Source Products; Irradiation; Radiation Therapy Equipment and Related Services; and Independent Clinical Medical and Laboratory Services, and Other Business. The Pharmaceuticals segment engages in the research, development, manufacture, and sale of imaging diagnostic and therapeutic radiopharmaceuticals; UBT kits and analyzers; and in vitro immunoassay diagnostic reagents and kits. The Radioactive Source Products segment provides medical and industrial radioactive sources products and related technical services. The Irradiation segment offers irradiation services to manufacturers of medical devices, food, traditional Chinese medicine, and cosmetics for sterilization; and EPC services for the design, manufacturing, and installation of gamma ray irradiation facilities. The Radiation Therapy Equipment and Related Services segment sells radiation therapy equipment; and provides related maintenance services. The Independent Clinical Medical and Laboratory Services, and Other Business segment provides independent clinical laboratory services with respect to hepatitis, endocrine, bone metabolism, cardiovascular disease, diabetes, and other diseases to hospitals and other medical institutions. The company was founded in 1983 and is headquartered in Beijing, China. China Isotope & Radiation Corporation is a subsidiary of China National Nuclear Corporation.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.